DECAPEPTYL
 |
|
|
Package:
SYRINGES/AMPOULES: 7 x 0.1 mg/1 ml.
Dosage:
Usual dose is 0.5 mg S.C. daily for 7 days, thereafter 0.1 mg S.C. daily as maintenance dose.
Prescribing Restrictions:
Indications:
Precocious puberty, prostate cancer, endometriosis, uterusleiomyoma, IVF.
Contra-Indications:
Non-hormone dependent carcinoma. Pregnancy and lactation. Any situation where endogenous sex-hormone activity is essential. Prostatic cancer: Should not be prescribed in patients presenting with spinal cord compression or evidence of spinal metastases.
Special Precautions:
Monitoring of the therapy should be performed according to the sex steroid serum levels. There may be a temporary flare up to the symptoms lasting a few days and will stop when hormone levels drop. Careful monitoring of follicular growth and luteal phase should be performed, especially in patients with polycystic ovaries.
Side Effects:
Hot flushes, sweating, reversible loss of libido and reversible impotence. See prescribing information for full details.
Men: The initial transient increase of serum testosterone has, in a few patients, been associated with a temporary aggravation of secondary symptoms of the disease. Close monitoring should be carried out during the first weeks of treatment. Patients at particular risk of developing ureteric obstruction should be carefully monitored, as should those at risk of developing spinal cord compression.
Women: Non-pregnancy should be confirmed. During the first month of treatment, patients should use non-hormonal contraceptives. Women should not use preparations containing estrogens during therapy. Uterus and myoma size should be regularly measured.
Less frequent: allergic reactions, headache, tiredness, gastralgia, recurrence of asthma, increased dysuria. See prescribing information for full details.
Drug Interactions:
None observed.
